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Four molecular species of heat-stable enterotoxins elaborated by a cholera toxin-producing strain of Vibrio cholerae O1 were isolated from its culture 
supernatant. The amino acid sequence of one of the enterotoxins was determined to be Phe-Ile-Lys-Gln-Val-Asp-Glu-Asn-Gly-Asn-Leu-Ile-Asp- 
Cys-Cys-Glu-Ile-Cys-Cys-Asn-Pro-Ala-Cys-Phe-Gly-Cys-Leu-Asn with three intramolecular disulfide linkages. The other enterotoxins had shorter 
amino acid sequences in the N-terminal regions, but possessed the same sequence in their C-terminal regions including the three disulfide linkages. 
The enterotoxins with the shorter N-terminal sequences showed more potent oxicities, and the minimum effective dose of the longest one with 
28 amino acid residues was 10-folds of that of the shortest one. 
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1. INTRODUCTION 
Vibrio cholerae belonging to the serogroup O1, the 
etiologic agent responsible for epidemics and pandemics 
of cholera, produce a heat-labile nterotoxin known as 
cholera toxin (CT) which is responsible for the drastic 
intestinal electrolyte secretion and fluid loss leading to 
the clinical state of cholera. In contrast, V. cholerae 
non-O1 do not have the epidemic potential but are asso- 
ciated with sporadic cases of gastroenteritis. CT pro- 
duction is rarely associated with V. cholerae non-O1 but 
strains of V. cholerae non-O1 are known to produce a 
heat-stable enterotoxin (ST) named NAG-ST [1] or Vc- 
H-ST [2]. Attempts to develop an effective live oral 
vaccine against he disease cholera have not been com- 
pletely successful because one-third of the human vol- 
unteers fed with genetically engineered candidate live 
oral cholera vaccine strains incapable of producing bio- 
logically active CT suffered from mild to moderate di- 
arrhoea [3]. This led investigators to search for ancillary 
secretogenic factors which might be responsible for the 
residual diarrhoea caused by the attenuated live oral 
cholera vaccine strains. It was recently found that an 
ST-like enterotoxin is produced by an environmental 
strain of CT-producing V. cholerae O1 [4]. The fact that 
V. cholerae O1 produces not only CT but also an ST- 
like toxin analogous to that of enterotoxigenic Escheri- 
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chia coli implied that a cholera vaccine should be pro- 
duced against both toxins for being completely effective. 
This formed the impetus for the present study in which 
we report for the first time the purification and sequence 
determination of the ST-like toxin (named O1-ST) ob- 
tained from the culture supernatant of a CT-producing 
strain of V. cholerae O1. 
2. EXPERIMENTAL 
2.1. Bacterial strain and culture conditions 
A CT-producing strain (GP156) of/~ cholerae O 1 (biotype ltor and 
serotype Inaba) originally isolated from Australia was the source of 
O1-ST [4]. The strain was cultured as previously described [4]. 
2.2. Isolation of O1-ST 
The culture supernatant of V. cholerae O1 GP156 was fractionated 
by ammonium sulfate precipitation (60% saturation). After centrifu- 
gation at 15,000 x g for 30 min at 4°C, the resulting pellet was dialyzed 
against deionized and distilled water (DDW), and then applied to a 
DEAE-Sephadex A-25 column (2 x 40 cm; acetate form) equilibrated 
with DDW. The column was washed with 1000 ml of DDW and eluted 
with a linear gradient from 0 to 1.0 M acetic acid (1000 ml of total 
volume), at a flow rate of 100 ml/h. The eluate was collected in 
fractions of 12 ml. An aliquot of each fraction was tested for toxicity 
in suckling mice and the active fractions were pooled. The toxic frac- 
tions were concentrated, ialyzed against DDW and then subjected to 
immunoaffinity chromatography on anti-NAG-ST monoclonal anti- 
body (mAb2F)-conjugated CNBr-Sepharose 4B column (1.6 x 4.5 cm) 
equilibrated with 100 mM sodium phosphate buffer (pH 7.0) [5]. The 
column was washed with 30 ml of the equilibration buffer and eluted 
with 15 ml of 100 mM Gly buffer (pH 2.5). The eluate was collected 
in fractions of 1.5 ml. The fractions containing toxic materials were 
concentrated and then purified further by reverse-phase high-perform- 
ance liquid chromatography (RP-HPLC). 
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2.3. High-perjormanee liquid chromatography 
The HPLC instrument used for peptide separation was a high- 
pressure gradient system which consisted of two Waters Model 510 
HPLC pumps. The column effluent absorbance was monitored at 214 
and 280 nm with use of Waters Absorbance Detectors Model 441 and 
440, respectively. The following elution programs were used in this 
study. Program I: a YMC R-ODS-5 column (4.6 x 250 ram) equili- 
brated with 10% CH~CN in 0.1% trifluoroacetic acid (TFA) was eluted 
with a linear gradient of CH~CN (1~50% in 40 rain), at a flow rate 
of 1.0 ml/min. Program II: a Cosmosil 5C18-AR column (4.6 x 250 
ram) equilibrated with 10 mM ammonium acetate (AcONH4) (pH 5.7) 
was eluted with a linear gradient of CH3CN (10 50% in 40 min), at 
a flow rate of 1.0 ml/min. Program III: a Cosmosil 5C18 column 
(4.6 x 150 ram) equilibrated with 10% CH3CN in 0.1% TFA was eluted 
with a linear gradient of CH3CN (10 50% in 40 min), at a flow rate 
of 1.0 ml/min. Program IV: a Cosmosil 5C18-AR column (4.6 x 150 
mm) equilibrated with 10% CH3CN in 10 mM AcONH4 (pH 5.7) was 
eluted with a linear gradient of CH3CN (10~ 50% in 40 rain), at a flow 
rate of 1.0 ml/min. Program V: a Cosmosil 5C18 column (4.6 x 150 
ram) equilibrated with 5% CH3CN in 0.1% TFA was eluted with a 
linear gradient of CH3CN (5 50% in 45 min), at a flow rate of 1.0 
ml/min. 
2.4. Amino aeid analysis, automated Edman degradation, and/ast atom 
bombardment (FAB) mass' spectrometo' 
Amino acid analysis was performed using a Hitachi L-8500 amino 
acid analyzer as documented previously [6]. Automated Edman degra- 
dation was carried out with a Shimadzu PSQ-1 gas-phase protein 
sequencer. FAB mass spectra were obtained with a J EOL JM S-HX100 
double-focusing mass spectrometer as previously described [6]. 
2.5. Peptide synthesis 
NAG-ST ( IDCCEICCNPACFGCLN) was synthesized as docu- 
mented previously [7]. N-t-Butyloxycarbonyl (Boc)-Leu-NAG-ST and 
Boc-Asn-Leu-NAG-ST were synthesized by condensation of the syn- 
thetic NAG-ST and Leu-NAG-ST with Boc-L-Leu N-hydroxysuccin- 
imide ester ( -ONSu) and Boc-L-Asn-ONSu, respectively. Boc group 
was removed by the treatment with 90% TFA. Amino acid composi- 
tions (mol/mol of Ala) and observed mass values ([M+H] +) of the 
synthetic peptides were as follows (the value in parentheses is shown 
as the theoretical value): Found for Leu-NAG-ST: Asp, 3.18 (3); Glu, 
0.98 (1); Pro, 1.03 (1); Gly, 1.04(1); Ala, 1.00 (1); l/2Cys, 5.55 (6); lie, 
1.88 (2); Leu, 2.06 (2); Phe, 1.12 (1). Observed m/z value: 1927.7 
(1927.7). Found for Asn-Leu-NAG-ST: Asp, 4.21 (4); Glu, 0.97 (1); 
Pro, 1.03 (1); Gly, 1.02 (1); Ala, 1.00 (1); 1/2 Cys, 5.36 (6); Ile, 1.83 
(2); Leu, 2.02 (2); Phe, 1.09 (1). Observed m/z value: 2041.6 (2041.7). 
2.6. Biological assay 
Toxic activity was assayed in suckling mice as previously described 
[8]. The fluid accumulation (FA) ratio was calculated as the ratio of 
the weight of entire intestine to that of the rest of body. An FA ratio 
of over 0.09 was considered to indicate a positive response. The min- 
imum effective dose (MED) was evaluated as the minimum amount 
generating the toxicity. 
3. RESULTS 
Crude toxin obtained from 15 L of the culture super- 
natant of V. cholerae O1 GP156 was partially purified 
by DEAE-Sephadex A-25 ion-exchange chromatogra- 
phy and mAb2F-conjugated CNBr-Sepharose 4B im- 
munoaffinity chromatography, as described in section 
2. The toxic fractions which eluted with 100 mM Gly 
buffer in affinity chromatography, were separated by 
RP-HPLC using Program I to four active peak frac- 
tions, as shown in Fig. 1. Each of these fractions was 
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Fig. I. Reverse-phase HPLC of the toxic fractions obtained by the 
immunoaffinity chromatography. Four active peak fractions indicated 
by arrows (1, 2, 3 and 4) were further subjected to rechromatog- 
raphy with the other solvent system (Program II, see section 2) to yield 
four pure peptides, OI-ST-1, -2, -3 and -4, respectively. 
subjected to rechromatography using Program II to 
give a pure peptide. Four different active peptides (O1- 
ST-l, -2, -3, and -4) were purified in final amounts of 
22.91, 40.10, 2.41, and 0.85 nmol, respectively. The 
amino acid compositions, mass values, and MED val- 
ues of the purified toxins are summarized in Table I. 
Differences in mass by 6 units between native and re- 
duced toxins in their FAB mass spectra indicate the 
presence of three intramolecular disulfide linkages. 
The amino acid composition and observed mass 
value of O1-ST-1 suggested that it has the same amino 
acid sequence (IDCCEICCNPACFGCLN) [1] and di- 
sulfide pairing mode (between Cys 3 and Cys s, Cys 4 and 
Cys  12, and Cys 7 and Cys 15) [9] as those of NAG-ST. In 
fact, O1-ST-I showed not only the same retention time 
as the synthetic NAG-ST on RP-HPLC using Programs 
III and IV but coeluted with synthetic NAG-ST as a 
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Fig. 2. Separation of an S. aureus V8 protease digest of S-carbox- 
ymethylated O I-ST-4 by RP-HPLC. 
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Table I 
Amino acid compositions, mass values, and MED values of heat- 
stable nterotoxins produced by ~ cholerae Ol GP156 
O1-ST-1 OI-ST-2 O1-ST-3  OI-ST-4 
Asp 3.13 (3) 3.13 (3) 4.08 (4) 5.92 (6) 
Glu 0.99 (1) 0.99 (1) 0.98 (1) 2.69 (3) 
Pro 1.00 (1) 1.02 (1) 0.98 (1) 1.04 (1) 
Gly 1.05 (1) 1.02 (1) 0.98 (1) 2.12 (2) 
Ala 1.00 (1) 1.00 (1) 1.00 (1) 1.00 (1) 
1/2 Cys 5.49 (6) 5.73 (6) 5.32 (6) 4.03 (6) 
Val 0.85 (1) 
lle 1.84 (2) 1.89 (2) 1.78 (2) 2.54 (3) 
Leu 1.00 (I) 2.06 (2) 1.96 (2) 2.06 (2) 
Phe 1.06 (1) 1.08 (1) 1.05 (1) 1.76 (2) 
Lys 0.80 (1) 
Total (17) (18) (19) (28) 
[M + H] + 
Intact 
Reduced 
1814.7 1927.7 2041.7 3072.5 
(1814.6) (1927.7) (2041.7) (3072.2) 
1820.7 1933.6 2047.8 3078.4 
(1820.7) (1933.7) (2047.8) (3078.3) 
MED (ng) 5.0 6.3 12 87 
(pmol) 2.8 3.3 5.9 28 
quences of  fragments 1 and 2 were determined by auto- 
mated Edman degradat ion to be Phe- I le-Lys-Gln-Asp-  
Glu and Asn-Gly -Asn-Leu- I le -Asp-CmCys-CmCys-  
Glu, respectively. The retention time of  f ragment 3 on 
RP-HPLC using Program V was identical to that of  a 
peptide, I le -CmCys-CmCys-Asn-Pro-A la -CmCys-Phe-  
G ly -CmCys-Leu-Asn,  which was obtained from an S. 
aureus V8 protease digest of  S-carboxymethylated syn- 
thetic NAG-ST.  Taken together all the evidence de- 
scribed above, the amino acid sequence of  O1-ST-4 was 
determined as shown in Table I. 
Taking the amino acid sequences of  O1-ST-1 and -4 
and the data of  O1-ST-2 shown in Table II into consid- 
eration, O1-ST-2 was suggested to be a peptide that one 
more Leu l inked to the N-terminus of  O1-ST-1, as 
shown in Table II. Chromatograph ic  analyses and bio- 
logical assay supported that O1-ST-2 was identical to 
the synthetic Leu-NAG-ST  (MED value: 6.9 ng, 3.6 
pmol).  According to the same procedure, the amino 
acid sequence of  O1-ST-3 was determined as shown in 
Table II. (The MED value of  the synthetic Asn-Leu-  
NAG-ST  was 12 ng, 5.9 nmol.) 
The amino acid composition is shown as a normalized value with 
alanine to have one residue, and the number in parentheses refers to 
the number of residues in the peptide found by sequencing. The mass 
value in parentheses denotes the theoretical mass value of the peptide. 
single peak under the both condit ions. In addit ion,  the 
MED value of  O1-ST-1 in the suckling mice assay was 
nearly identical to the value (5.4 ng, 3.0 pmol)  of  the 
synthetic NAG-ST .  
Next, O1-ST-4 was subjected to a gas-phase protein 
sequencer. The N-terminal  sequence of  the peptide was 
determined to be Phe- I le-Lys-Gln-Val -Asp-Glu-Asn-  
Gly-Asn-Leu- I le-Asp- .  Then, O1-ST-4 was treated with 
iodoacetic acid in the presence of  dithiothreitol ,  and the 
resulting S-carboxymethylated peptide was digested 
with Staphylococcus aureus V8 protease in 50 mM 
NH4HCO3 (pH 7.8) at 37°C for 7 h. Fract ionat ion of  
the digest by RP-HPLC with use of  Program V yielded 
three peptide fragments (Fig. 2). The amino acid se- 
4. D ISCUSSION 
In the present study, four molecular  species of  STs 
e laborated by a CT-producing strain of  V. cholerae O1 
were isolated and their pr imary structures determined. 
They had the same amino acid sequence but varied in 
their length at the N-terminal  port ions. A l though the 
amino acid sequence (CCE ICCNPACFGC)  essential 
for expression of  the biological activity was completely 
identical among the peptides [9,10], their toxicities be- 
came more potent by the loss of  the N-terminal  amino 
acids. One of  the enterotoxins produced by V. cholerae 
O1, O1-ST-1, was the same toxin as that e laborated by 
V. cholerae non-O1 (named NAG-ST)  [1] and V. mim- 
icus (named VM-ST) [1 1]. Furthermore,  the pr imary 
structure of  O1-ST-2 was identical to that of  Vc-H-ST 
produced by V. cholerae non-O1 serogroup Hakata  [2]. 
Very recently, the nucleotide sequence of  the structural 
gene encoding O1-ST has been determined [12]. All  of 
the determined amino acid sequences were consistent 
Table I 1 
Amino acid sequences of O1-STs and their comparisons with those of STs produced by the other bacteria belonging to the genus Vibrio 
OI-ST-I: 
OI-ST-2: 
OI-ST-3: 
O1-ST-4: 
NAG-ST: 
Vc-H-ST: 
VM-ST: 
Ile-Asp-Cys-Cys-Glu-Ile-Cys-Cys-Asn-Pro-Ala-Cys-Phe-Gly-Cys-Leu-Asn 
Leu-Ile-Asp-Cys-Cys-Glu-lle-Cys-Cys-Asn-Pro-Ala-Cys-Phe-Gly-Cys- Leu-A n 
Asn-Leu-Ile-Asp-Cys-Cys-Glu-Ile-Cys-Cys-Asn-Pro-Ala-Cys-Phe-Gly-Cys-Leu-Asn 
P he-I•e-Lys-G•n-Va•-Asp-G•u-Asn-G•y-Asn-Leu-I•e-Asp-Cys-Cys-G•u-I•e-Cys-Cys-Asn-Pro-A•a-Cys-Phe-G•y-Cys-Leu-Asn 
Ile-Asp-Cys-Cys-Glu-Ile-Cys-Cys-Asn-Pro-Ala-Cys-Phe-Gly-Cys-Leu-Asn 
Leu-Ile-Asp-Cys-Cys-Glu-Ile-Cys-Cys-Asn-Pro-Ala-Cys-Phe-Gly-Cys- Leu-A n 
lle-Asp-Cys-Cys-Glu-Ile-Cys-Cys-Asn-Pro-Ala-Cys-Phe-Gly-Cys- Leu-Asn 
NAG-ST, Vc-H-ST and VM-ST are produced by E cholerae non-O1 [1], I4 cholerae non-Ol serogroup Hakata [2], and 1( mimic.us [ll], respectively. 
85 
Volume 326, number 1,2,3 FEBS LETTERS July 1993 
with those deduced from the nucleotide sequence. Thus, 
the four O1-STs should have originated from a single 
structural gene. From several ines of evidence, it was 
suggested that an immature form of toxin is excreted 
into the extracellular media by crossing through the 
outer membrane without complete proteolytic process- 
ing. The nucleotide sequence of the O1-ST gene is highly 
homologous to that of the NAG-ST gene of V. cholerae 
non-O1 [12,13]. However, only one species of toxin 
(NAG-ST) could be recovered from the culture super- 
natant of V. cholerae non-O1 [1]. The difference in gene 
products between V. cholerae O1 and non-O1 may be 
ascribed to the specificity of proteases secreted into the 
periplasmic space and extracellular media of these bac- 
teria [14]. 
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